Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå : ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø - Á¦Ç° À¯Çüº°, ºÐÀÚ À¯Çüº°, Ç¥Àû ÀûÀÀÁõº°, Ä¡·á ¿µ¿ªº°, Åõ¿© °æ·Îº°, ÁÖ¿ä Áö¿ªº°
Human Microbiome Market Distribution : Industry Trends and Global Forecasts by Type of Product, Type of Molecule, Target Indication, Therapeutic Area, Route of Administration and Key Geographical Regions
»óǰÄÚµå : 1762526
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 552 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,650,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,699,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 14,688,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 24,943,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå : °³¿ä

¼¼°èÀÇ Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå ±Ô¸ð´Â 2035³â±îÁöÀÇ ¿¹Ãø ±â°£ Áß 20.4%ÀÇ CAGR·Î È®´ëÇϸç, ÇöÀç 7¾ï 9,100¸¸ ´Þ·¯¿¡¼­ 2035³â±îÁö 60¾ï 9,100¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­¿¡¼­´Â ½ÃÀå ±Ô¸ð¿Í ½ÃÀå ±âȸ¸¦ ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö·Î ±¸ºÐÇÕ´Ï´Ù.

Á¦Ç° À¯Çü

ºÐÀÚ À¯Çü

Ç¥Àû ÀûÀÀÁõ

Ä¡·á ¿µ¿ª

Åõ¿© °æ·Î

ÁÖ¿ä Áö¿ª

Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå : ¼ºÀå°ú µ¿Çâ

¹Ì»ý¹°À̶ó°í ÇÏ¸é °ú°Å¿¡´Â À¯ÇØÇÑ Áúº´ÀÇ ¿øÀÎ ¹°ÁúÀ̶ó´Â À̹ÌÁö°¡ °­ÇßÀ¸³ª, ÀÎü ³»¿¡¼­ ƯÁ¤ À¯ÀÍÇÑ ¹Ì»ý¹° ±ºÁýÀÌ ¹ß°ßµÇ¾ú½À´Ï´Ù. Àΰ£°ú ¼¼±Õ, È¿¸ð, ¿ø»ýµ¿¹° µî ´Ù¾çÇÑ ¹Ì»ý¹° Á¾Àº »óÈ£ À¯ÀÍÇÑ °ü°è·Î °øÁ¸ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àΰ£ÀÇ Àå³» ¹Ì»ý¹°Àº ¾à 100Á¶ °³ÀÇ ¹Ì»ý¹°·Î ±¸¼ºµÇ¾î ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ ¸¸ÇÑ Á¡Àº ÀÌ ¼öÄ¡°¡ ÀÎüÀÇ ÃÑ ¼¼Æ÷ ¼ö¸¦ Å©°Ô »óȸÇÑ´Ù´Â Á¡ÀÔ´Ï´Ù.

Human Microbiome Market-IMG1

´ëºÎºÐÀÇ ¹Ì»ý¹°Àº ´Ù¸¥ ¹æ¹ýÀ¸·Î´Â ¾òÀ» ¼ö ¾ø´Â ÇüÁú°ú ´É·ÂÀ» ºÎ¿©ÇÔÀ¸·Î½á Àΰ£¿¡°Ô Å« ÀÌÀÍÀ» °¡Á®´Ù ÁÝ´Ï´Ù. Àå³»¼¼±ÕÀÇ °Ç°­ÇÑ ´Ù¾ç¼ºÀº ¸é¿ª·ÂÀ» ³ôÀÌ°í ±¤¹üÀ§ÇÑ °Ç°­»óÀÇ ÀÌÁ¡À» Á¦°øÇÒ ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀ» ±â¹ÝÀ¸·Î ÇÑ »ì¾ÆÀÖ´Â ¹ÙÀÌ¿À Ä¡·áÁ¦/Áø´ÜÁ¦ °³¹ß ¾÷üµéÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß ³ë·ÂÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, µ¶ÀÚÀûÀÎ Á¦Ç° Èĺ¸¹°ÁúÀÇ ÀÓ»ó ÁøÀüÀ̶ó´Â Ãø¸é¿¡¼­ Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀ̿Ȱú °Ç°­ÀÇ ¹ÐÁ¢ÇÑ ¿¬°ü¼ºÀ¸·Î ÀÎÇØ »óÀç ¹Ì»ý¹°ÀÇ Á¶ÀÛÀ» ±â¹ÝÀ¸·Î ÇÑ ¼ö¸¹Àº Ä¡·áÀû °³ÀÔÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀå ÇöȲÀ» Á¶»çÇÏ°í ¾÷°è³» ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

ÀÌ Áß ¾à 80%´Â ½ÃÀå¿¡¼­ »ç¿ë °¡´ÉÇϸç, ³ª¸ÓÁö´Â °³¹ß Áß¿¡ ÀÖ½À´Ï´Ù.

Human Microbiome Market-IMG2
Human Microbiome Market-IMG3

Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ½ÃÀåÀÇ Âü¿© ±â¾÷ ¿¹

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

Á¦3Àå ¼­·Ð

Á¦4Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦ : ½ÃÀå ±¸µµ

Á¦5Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦ : ±â¾÷°ú ¾àÁ¦ °³¿ä

Á¦6Àå ÀÓ»ó½ÃÇè ºÐ¼® : Àΰ£ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦

Á¦7Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áø´Ü ¹× ½ºÅ©¸®´×/ÇÁ·ÎÆÄÀϸµ °Ë»ç : ½ÃÀå ±¸µµ

Á¦8Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áø´Ü ¹× ½ºÅ©¸®´×/ÇÁ·ÎÆÄÀϸµ °Ë»ç ÇÁ·Î¹ÙÀÌ´õ : ±â¾÷ °³¿ä

Á¦9Àå ºÐº¯ ¹Ì»ý¹° À̽Ä(FMT)

Á¦10Àå ÀÓ»ó½ÃÇè ºÐ¼® : ºÐº¯ ¹Ì»ý¹° À̽Ä

Á¦11Àå ¸Å·Â°ú °æÀï·Â(AC) ¸ÅÆ®¸¯½º

Á¦12Àå ´ëÇü Á¦¾àȸ»çÀÇ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È °ü·Ã ±¸»ó

Á¦13Àå ½ºÅ¸Æ®¾÷ °ÇÀü¼º ÁöÇ¥

Á¦14Àå ÁÖ¿ä Ä¡·á ¿µ¿ª

Á¦15Àå ÆÄÆ®³Ê½Ê°ú Çù¾÷

Á¦16Àå ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ ºÐ¼®

Á¦17Àå »ç·Ê ¿¬±¸ : ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦ ¹× »ýü ¹ÙÀÌ¿À Ä¡·áÁ¦ °è¾à ¼­ºñ½º

Á¦18Àå ºòµ¥ÀÌÅÍ¿Í ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·á

Á¦19Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Ä¡·áÁ¦ : ½ÃÀå ¿¹Ãø°ú ±âȸ ºÐ¼®

Á¦20Àå ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Áø´Ü : ½ÃÀå ¿¹Ãø°ú ±âȸ ºÐ¼®

Á¦21Àå ºÐº¯ ¹Ì»ý¹° ÀÌ½Ä : ½ÃÀå ¿¹Ãø°ú ±âȸ ºÐ¼®

Á¦22Àå »ç·Ê ¿¬±¸ : ºñÀǾàǰ »ê¾÷¿¡¼­ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Á¦Ç°

Á¦23Àå °á·Ð

Á¦24Àå À̱×Á¦Å¥Æ¼ºê ÀλçÀÌÆ®

Á¦25Àå ºÎ·Ï I : Ç¥Çü½Ä µ¥ÀÌÅÍ

Á¦26Àå ºÎ·Ï II : ±â¾÷ ¹× Á¶Á÷ ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

HUMAN MICROBIOME MARKET: OVERVIEW

As per Roots Analysis, the global human microbiome market is estimated to grow from USD 791 million in the current year to USD 6,091 million by 2035, at a CAGR of 20.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

Type of Molecule

Target Indication

Therapeutic Area

Route of Administration

Key Geographical Regions

HUMAN MICROBIOME MARKET: GROWTH AND TRENDS

The term microorganism were previously associated with harmful disease-causing agents, until the discovery of certain beneficial microbial colonies in the human system. Humans and a variety of microbial species of bacteria, yeast and protozoa, are known to co-exist in mutually beneficial relationships. Moreover, it is estimated that the human gut microbiome consists of about 100 trillion microorganisms. Notably, this figure significantly outnumbers the total number of cells in the human body.

Human Microbiome Market - IMG1

The majority of microorganisms provide significant benefits to humans by conferring traits and capabilities that would otherwise be absent. The healthy variety of bacteria in the gut has significant potential to enhance immunity and offer a wide range of health benefits. This has led to extensive research and development efforts by human microbiome based live biotherapeutics / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic. In addition, owing to the strong association between the human microbiome and health, a myriad of therapeutic interventions based on manipulation of commensal microbes are under development.

HUMAN MICROBIOME MARKET: KEY INSIGHTS

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

Of these, around 80% of the tests are available in the market, while rest are under development.

Human Microbiome Market - IMG2
Human Microbiome Market - IMG3

Example Players in the Human Microbiome Market

HUMAN MICROBIOME MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS

7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

9. FECAL MICROBIOTA THERAPY (FMT)

10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY

11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS

13. START-UP HEALTH INDEXING

14. KEY THERAPEUTIC AREAS

15. PARTNERSHIPS AND COLLABORATIONS

16. FUNDING AND INVESTMENT ANALYSIS

17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

18. BIG DATA AND MICROBIOME THERAPEUTICS

19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â